This site is intended for healthcare professionals
Managing Osteoarthritis-associated Pain
Declaration of sponsorship Pfizer and Lilly


Declaration of sponsorship Pfizer and Lilly
Read time: 265 mins
Last updated:13th Apr 2021
Did you know that treating pain in osteoarthritis (OA) is changing? Guidelines now highlight the importance of personalised pain management strategies and while the heterogeneous nature of OA means that disease-modifying treatment has been elusive, there are emerging therapies focussed on pain control which are currently in development.

Osteoarthritis (OA) is the most prevalent chronic joint disease and a prominent cause of pain, distress and disability1. The burden of OA to patients is often underestimated2 and the health economic burden is growing with increased life expectancy and risk factors such as obesity and additional comorbidities1

Current pharmacological treatments for OA are focussed on symptomatic analgesia. Guideline changes have downgraded the use of paracetamol and opioids and highlighted the need for personalised pain management3–5. There are, however, emerging therapies for OA pain control which could impact the burden of OA in the future1.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest